1. Home
  2. JXG vs GNPX Comparison

JXG vs GNPX Comparison

Compare JXG & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JX Luxventure Limited

JXG

JX Luxventure Limited

HOLD

Current Price

$4.07

Market Cap

7.5M

Sector

N/A

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.06

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JXG
GNPX
Founded
N/A
2009
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
6.4M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
JXG
GNPX
Price
$4.07
$2.06
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.2K
1.1M
Earning Date
11-05-2025
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
5.26
N/A
Revenue
$46,835,624.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.77
N/A
Revenue Growth
21.68
N/A
52 Week Low
$3.01
$1.71
52 Week High
$45.15
$55.00

Technical Indicators

Market Signals
Indicator
JXG
GNPX
Relative Strength Index (RSI) 38.64 41.61
Support Level $3.91 $1.99
Resistance Level $4.24 $2.29
Average True Range (ATR) 0.33 0.28
MACD 0.04 -0.04
Stochastic Oscillator 33.56 10.74

Price Performance

Historical Comparison
JXG
GNPX

About JXG JX Luxventure Limited

JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: